Asia Oceania Journal of Nuclear Medicine and Biology

Asia Oceania Journal of Nuclear Medicine and Biology

Both F-18 FDG-avidity and Malignant Shape of Cervical Lymph Nodes on PET/CT after Total Thyroidectomy Predict Resistance to High-dose I-131 Therapy in Patients with Papillary Thyroid Cancer

Document Type : Original Article

Authors
Byung Hyun Byun 1
Seong Young Kwon 1
Ari Chong 2
Jahae Kim 2
Su Woong Yoo 1
Jung-Joon Min 1
Ho-Chun Song 2
Henry Hee-Seung Bom 1, 3
1 Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Republic of Korea
2 Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea
3 President, AOFNMB
10.7508/aojnmb.2013.01.003
Abstract
Objective(s): Resistance of metastatic lymph nodes (LNs) to high dose I-131 therapy is associated with high morbidity in patients with differentiated thyroid cancer. We evaluated the role of F-18 FDG PET/CT in the prediction of resistance to high dose I-131 therapy in patients with papillary thyroid cancer.
Methods: The subjects were 307 patients who underwent total or near total thyroidectomy followed by high dose (5.55-6.66 GBq) I-131 therapy. We divided the patients into three subgroups by visual assessment of regional LNs: FDG-avid LNs with a malignant shape on CT (PET/CT-positive group), FDG-avid LNs with a benign shape on CT (PET/CT-intermediate group) and no FDG-avid lesion (PET/CT-negative group). We measured the maximum SUV (SUVmax) of FDG-avid LNs in each patient. The presence or absence of focal increased uptake of I-131 was evaluated by whole body scan (WBS), and was denoted as WBS-positive group or WBS-negative group, respectively. Resistance to therapy was defined as presence of thyroglobulin (Tg) in serum (Tg ≥1.0 ng/ml) 3-6 months after I-131 therapy. Univariate and multivariate analyses were performed to determine the relationship between resistance to I-131 therapy and various clinico-pathologic variables.
Results: PET/CT-positive, intermediate, and negative groups included 20 (6.5%), 44 (14.3%) and 243 (79.2%) patients, respectively. The mean SUVmax was significantly higher in the PET/CT-positive group than that of the PET/CT-intermediate group (4.6 vs. 2.7, P <0.001). Univariate analysis revealed that the PET/CT-positive group (P <0.001), T2-4 stage (P <0.001), N1b stage (P = 0.001), lower dose (5.55 GBq) of I-131 (P <0.001), and the WBS-positive group (P = 0.029) were associated with resistance to therapy. In multivariate analysis, the PET/CT-positive group, lower dose of I-131, N1b stage, and T2-4 stage remained significant with odds ratios of 10.07 (P <0.001), 3.82 (P <0.001), 3.58 (P = 0.001), and 2.53 (P = 0.009), respectively.
Conclusion: FDG-avidity and malignant shape of cervical LNs on pre-therapy FDG PET/CT were a strong risk factors predicting resistance to high dose I-131 therapy. A lower dose of administered I-131 (5.55 GBq) and more extensive tumors (T2-4 and N1b) were also associated with resistance to high dose I-131 therapy.
Keywords
F-18 FDG PET/CT
Resistance to I-131 therapy
Cervical lymph node
Papillary thyroid cancer

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.

    1. Ozaki O, Ito K, Kobayashi K, Suzuki A, Manabe Y. Modified neck dissection for patients with nonadvanced, differentiated carcinoma of the thyroid. World J Surg. 1988;12(6):825-9.
    2. Shaha AR, Shah JP, Loree TR. Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid. Am J Surg. 1996;172(6):692-4.
    3. Harwood J, Clark OH, Dunphy JE. Significance of lymph node metastasis in differentiated thyroid cancer. Am J Surg. 1978;136(1):107-12.
    4. Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am. 2007;36(3):807-22, vii-viii.
    5. Sweeney DC, Johnston GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am. 1995;24(4):803-39.
    6. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1986;63(4):960-7.
    7. Oh JR, Byun BH, Hong SP, Chong A, Kim J, Yoo SW, et al. Comparison of (1)(3)(1)I whole-body imaging, (1)(3)(1)I SPECT/CT, and (1)(8)F-FDG PET/CT in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(8):1459-68.
    8. Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, et al. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT. Clin Nucl Med. 2010;35(1):6-11.
    9. Pacini F, Cetani F, Miccoli P, Mancusi F, Ceccarelli C, Lippi F, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18(4):600-4.
    10. Iwano S, Kato K, Ito S, Tsuchiya K, Naganawa S. FDG-PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer. Ann Nucl Med. 2012;26(3):207-13.
    11. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, et al. Resistance of (18f)-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;11(12):1169-75.
    12. Giovanella L, Maffioli M, Ceriani L, De Palma D, Spriano G. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma. Clin Chem Lab Med. 2009;47(8):1001-4.
    13. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471-4.
    14. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiologic criteria. Radiology. 1990;177(2):379-84.
    15. Grabellus F, Nagarajah J, Bockisch A, Schmid KW, Sheu SY. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med. 2012;37(2):121-7.
    16. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37(9):1468-72.
    17. Yoshio K, Sato S, Okumura Y, Katsui K, Takemoto M, Suzuki E, et al. The local efficacy of I-131 for F-18 FDG PET positive lesions in patients with recurrent or metastatic thyroid carcinomas. Clin Nucl Med. 2011;36(2):113-7.
    18. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23(10):1409-15.
    19. Karam M, Feustel PJ, Postal ES, Cheema A, Goldfarb CR. Successful thyroid tissue ablation as defined by a negative whole-body scan or an undetectable thyroglobulin: a comparative study. Nucl Med Commun. 2005;26(4):331-6.
    20. Lin JD, Kao PF, Chao TC. The effects of radioactive iodine in thyroid remnant ablation and treatment of well differentiated thyroid carcinoma. Br J Radiol. 1998;71(843):307-13.
    21. Oh SW, Moon SH, Park do J, Cho BY, Jung KC, Lee DS, et al. Combined therapy with 131I and retinoic acid in Korean patients with radioiodine-refractory papillary thyroid cancer. Eur J Nucl Med Mol Imaging. 2011;38(10):1798-805.
    22. Chung J-K, Youn H, Kang J, Lee H, Kang K. Sodium Iodide Symporter and the Radioiodine Treatment of Thyroid Carcinoma. Nucl Med Mol Imaging. 2010;44(1):4-14.
    23. Capdevila J, Iglesias L, Halperin I, Segura A, Martinez-Trufero J, Vaz MA, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012;19(2):209-16.
    24. Paeng J, Kang K, Park D, Oh S, Chung J-K. Alternative Medical Treatment for Radioiodine-Refractory Thyroid Cancers. Nucl Med Mol Imaging. 2011;45(4):241-7.
    25. Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D’Amico D, et al. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Q J Nucl Med Mol Imaging. 2008;52(1):2-8.
    26. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-214.
    27. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? Eur J Nucl Med. 1987;12(10):500-2.
    28. Beierwaltes WH. The treatment of thyroid carcinoma with radioactive iodine. Semin Nucl Med. 1978;8(1):79-94.
    29. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low-risk thyroidcancer. N Engl J Med. 2012;366(18):1663-73.
    30. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab. 2003;88(4):1433-41.